Prostate Cancer Vaccine May Improve Survival
Provenge Extends Life When Other Treatments Fail
Kantoff points out the study was relatively small, including only 127 men -- compared with a thousand or more who frequently participate in a single chemotherapy trial.
As a result, Kantoff says the positive findings could have been the result of "unforeseen biologic differences in the two groups." In this instance, factors related to each man's cancer and overall health might have actually been responsible for the outcome currently being credited to the prostate cancer vaccine.
The only way to know for sure, he says, is to duplicate the results in a much larger clinical trial --something the researchers are hoping to accomplish.
Still, Kantoff says the findings represent a major step forward in a potentially new and perhaps less toxic treatment for prostate cancer.
"The magnitude of the impact of this trial is remarkably large," he says, indicating that, if proven in larger trials, it could dramatically change prostate cancer treatment.